Retrospective review of mitomycin C use as third‐line chemotherapy in metastatic colorectal cancer

The aim of this review was to determine the therapeutic value of the combination of mitomycin C with either infusional 5‐fluorouracil or oral capecitabine in metastatic colorectal cancer when used as third‐line treatment or beyond in the setting of routine clinical practice. We retrospectively reviewed 18 patients with advanced colorectal cancer who received this combination at our institution after the failure of two lines of prior treatment. All the patients were assessable for toxicity and survival and 14 for tumor response. The median age of the patients was 61 (range 39–78). Of these, 72% were male and 78% had Eastern Cooperative Oncology Group performance status 0 or 1. Eighty nine percent of the patients had metastatic involvement of the liver and five patients had at least three sites of metastatic involvement. All patients had received at least two lines of chemotherapy and had progressed on an oxaliplatin‐containing regimen. Most of the patients had previously received an irinotecan‐containing regimen, and a third had received prior biological agents. Overall, none of the patients achieved either complete or partial responses. Two patients (11%) achieved stable disease and 12 patients (67%) had progressive disease. The median progression‐free survival was 2.7 months (range 0.5–8.8) and the median overall survival was 5.4 months (range 1.3–31.2). This chemotherapy regimen was well tolerated with an acceptable toxicity profile. The results of our review confirm the low efficacy of combination mitomycin C in heavily pretreated Australian patients with advanced colorectal cancer. This review confirms that it has no role after two lines of modern combination chemotherapy regimens and recommends that focus should be placed on investigating newer agents for good performance status patients progressing after these treatments.     

Sequence polymorphism of the group 1 allergen of Bermuda grass pollen

BACKGROUND: Cyn d 1, the major allergen of Bermuda grass pollen, consists of a number of isoforms. OBJECTIVE: To examine the extent of sequence variation of Cyn d 1 isoforms at the molecular level. METHODS: A Bermuda grass pollen lambdaZAP II cDNA expression library was immunoscreened with anti-Cyn d 1 monoclonal antibodies. The reactive clones were isolated, subcloned into Escherichia coli, and sequenced. Some of them were expressed in the yeast Pichia pastoris to obtain recombinant Cyn d 1 proteins. RESULTS: Ten cDNA clones were obtained, all these clones encode the full length of Cyn d 1 protein. Their deduced mature proteins can be grouped into: the long ones with 246 amino acids, and the short ones with 244 amino acids. The last two amino acids (AG) of the long Cyn d 1 are deleted in the short Cyn d 1. The remaining amino acid sequences share more than 98% identity; a total of nine amino acid variations were observed. Two recombinant Cyn d 1 proteins (rCyn d 3-2 and rCyn d 5-4) with three amino acid substitutions showed differential IgE-binding profiles. CONCLUSION: The present study extended our understanding of the primary structure of isoforms of Cyn d 1.     

ATL Ultramark 9HDI B超直流变换器故障原理及检修

本文介绍了ATL UM9HDI B超直流变换器的工作原理、常见故障及检修的方法。     

椎间孔镜BEIS技术治疗老年腰椎侧隐窝狭窄症

目的 :探讨经皮椎间孔镜BEIS(broad easy immediate surgery)技术治疗老年腰椎侧隐窝狭窄症的安全性及有效性。方法:2014年2月至2016年5月,采用经皮椎间孔镜BEIS技术治疗21例老年腰椎侧隐窝狭窄症患者,其中男13例,女8例,年龄70~85岁,平均74.3岁。记录术前、术后1、12个月腿痛视觉模拟评分(visual analogue scale,VAS)及Oswestry功能障碍指数(Oswestry Disability Index,ODI),统计分析术前及术后各时间点的差异。用改良MacNab标准评价疗效。结果 :21例患者均顺利完成手术,手术时间90~130 min,平均110 min。所有病例获得随访,时间12~38个月,平均18个月。术前、术后1、12个月的VAS评分分别为8.47±1.23、1.78±0.72、0.68±0.32,术前、术后1、12个月的ODI评分分别为32.48±10.03、19.53±3.55、5.15±1.02,术后2个时间点随访的VAS评分及ODI评分,均较术前明显改善(P0.05)。术后12个月采用改良Mac Nab标准评定疗效,优14例,良5例,可2例。术后出现下肢感觉异常1例,给予保守治疗,术后3周恢复。1例肺气肿患者术后出现肺部感染,经抗感染治疗后控制。无椎体或椎间隙感染、血管及神经根损伤、硬脊膜撕裂脑脊液漏等并发症发生。结论:经皮椎间孔镜BEIS技术治疗老年腰椎侧隐窝狭窄症是一种安全、有效、微创的手术方法,但技术难度较大,特别是对于严重的椎间孔狭窄,经椎间孔入路操作困难,应严格把握手术适应证。术后可能并发神经激惹及术后感觉异常。     

The reproducibility and comparability of tests of the peripheral chemoreflex: comparing the transient hypoxic ventilatory drive test and the single-breath carbon dioxide response test in healthy subjects

Abstract. Both the transient hypoxic ventilatory drive test and the single-breath carbon dioxide (CO₂) response test have been used to assess peripheral chemoreflex sensitivity. We tested their comparability in 14 healthy adults (10 men, aged 31–73 years, mean 55.4 years). The within-subject reproducibility of both tests was also assessed ( n = 7 for each). The mean transient hyoxic ventilatory response was 0.287 ± 0.0591min^-1 (%Sao₂)^-1 (mean ± SEM, range 0.018–0.718) and single-breath CO₂ response was 0.276 ± 0.0411 min^-1T^-1 (range 0.081–0.501). Both tests were reproducible with a mean coefficient of variation of 20.1% and 17.7%, respectively. There was, however, no significant correlation between the results of the transient hypoxic and single-breath CO₂ tests when data were compared by linear regression analysis ( r = 0.23, P = 0.43), suggesting that separate pathways of the peripheral chemoreflex existed for hypoxia and hypercapnia, respectively, and that these tests were specific for each. The authors conclude that these tests are reproducible but need to be used in combination for an adequate assessment of the peripheral chemoreflex.     

慢性HBV携带者的肝组织损伤研究

目的:分析慢性HBV携带者的肝组织病理改变,为慢性HBV携带者的诊治提供依据。方法:113例慢性HBV携带者进行肝组织学检查和血清学、病毒核酸检测。结果:57.52%的慢性HBV携带者肝组织炎症(G)在2级以上,HBeAg阴性携带者G≥2占70.59%,符合抗病毒治疗指征。肝组织炎症活动程度分级与HBV-DNA滴度无相关性(P>0.05),肝组织炎症分级与纤维化分期显著相关(χ2=51.589,P<0.001)。结论:对慢性HBV携带者应建议行肝脏穿刺检查,尤其是HBeAg阴性的慢性HBV携带者,以提高诊断的准确性并进行合理治疗。     

子宫内膜样腺癌中GELSOLIN和PTEN蛋白的表达及其临床意义

目的探讨子宫内膜样腺癌发生、发展的分子生物学机制,为子宫内膜样腺癌的生物学特性的评定及靶向基因治疗,寻找新的分子生物学指标。方法采用免疫组化SP法对100例不同子宫内膜组织进行两蛋白的检测,采用秩和检验及Spearman等级相关分析进行统计学处理。结果 GELSOLIN的表达情况N组优于A组及E组(P<0.05);无淋巴结转移者优于有淋巴结转移者(P<0.05)、浸润深度<1/2肌层者优于≥1/2肌层者(P<0.05)。PTEN的表达情况N组优于A组及E组(P<0.05);G1期优于G2+G3期、浸润深度<1/2肌层者优于≥1/2肌层者(P<0.05)。GELSOLIN与PTEN在肿瘤中的表达无相关性(P>0.05)。结论 GELSOLIN或PTEN表达降低能促进子宫内膜样腺癌的发生、发展,两蛋白的作用通路可能无交叉,互不影响。     

第三方调解解决医患纠纷的实践与思考

通过非诉讼替代式解决方式化解医疗纠纷,使医患纠纷在第一时间内转移至院外,既维护了医疗机构的正常医疗秩序,公平、公正、方便、快捷的依法维护了医患双方的利益,又节约解决纠纷的成本,提高了效率,是解决医患矛盾的有效途径。     

掌握医疗器械信息降低采购成本

掌握最新、权威、准确、可靠的医疗器械准入、技术、市场价格等信息,并使之公开透明,才能科学有效地为医疗器械的计划预算、技术论证、效益分析、购置组织、合同签署等提供科学决策依据.